DOCSLIB.ORG

List of Generic Vs. Trade Names Tm

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Generic Vs. Trade Names Tm LIST OF GENERIC VS. TRADE NAMES TM Enhancing Clinical Excellence The following compilation of trade vs. generic drugs was put together for your convenience & reference. It is in no way complete, please refer to Drugs@FDA at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ for complete and most recent list. Generic Trade Generic Trade Generic Trade Abacavir ZIAGEN Anagrelide AGRYLIN Bimatoprost LUMIGAN Abciximab REOPRO Anastrozole ARIMIDEX Bisacodyl DULCOLAX Acarbose PRECOSE Anisindione MIRADON Bismuth subgallate DEVROM Acebutolol SECTRAL Anistreplase EMINASE Bismuth subsalicylate PEPTO-BISMOL Acetaminophen TYLENOL ANTHRA-DERM Bisoprolol ZEBETA Acetazolamide DIAMOX Anthralin DRITHOCREME Bitolterol TORNALATE Acetohexamide DYMELOR MICANOL Bivalirudin ANGIOMAX Acetylcysteine MUCOMYST Apixaban ELIQUIS Bosentan TRACLEER Acetylsalicylic acid See Aspirin Apraclonidine IOPIDINE Botulinum toxin BOTOX ACTH See Corticotropin Argatroban ARGATROBAN Bretylium BRETYLOL Acyclovir ZOVIRAX Asparaginase ELSPAR Brimonidine ALPHAGAN Adapalene DIFFERIN Aspart NOVOLOG Brinzolamide AZOPT Adenosine ADENOCARD ECOTRIN Bromocriptine PARLODEL Aspirin Albendazole ALBENZA ASPERGUM Brompheniramine DIMETANE PROVENTIL Atenolol TENORMIN Budesonide RHINOCORT Albuterol VENTOLIN Atorvastatin LIPITOR Budesonide ENTOCORT Capsules/Enema cAPSULES/ENEMA Alclometasone ACLOVATE Atovaquone MEPRON Bumetanide BUMEX Alemtuzumab CAMPATH Atovaquone-Proguanil MALARONE Buprenorphine BUPRENEX Alendronate FOSAMAX Atracurium TRACRIUM Bupropion WELLBUTRIN Alfuzosin UROXATRAL Auranofin RIDAURA Buspirone BUSPAR LOPURIN Azatadine OPTIMINE Allopurinol Busulfan MYLERAN ZYLOPRIM Azathioprine IMURAN Butenafine MENTAX Almotriptan AXERT AZELEZ Azelaic acid Butoconazole FEMSTAT Alprazolam XANAX FINEVIN Butorphanol STADOL CAVERJECT Azelastine OPTIVAR Alprostadil Cabergoline DOSTINEX PROSTIN VR Azithromycin ZITHROMAX Calcipotriene DOVONEX AMPHOGEL Aztreonam AZACTAM Aluminum hydroxide MIACALCIN ALU-CAP Bacitracin AK-TRACIN Calcitonin CALCIMAR Amantadine SYMMETREL Baclofen LIORESAL Calcitriol ROCALTROL Amcinonide CYCLOCORT Balsalazide COLAZAL TUMS Amikacin AMIKIN Basiliximab SIMULECT Calcium carbonate CALTRATE Amiloride MIDAMOR BECONASE Beclomethasone OSCAL Aminocaproic acid AMICAR VANCENASE Candesartan ATACAND Aminophylline PHYLLOCONTIN Benazepril LOTENSIN ZOSTRIX Amiodarone CORDARONE Benzathine penicillin BICILLIN Capsaicin CAPSIN ELAVIL Benzonatate TESSALON Amitriptyline CAPZASIN ENDEP BENZAC Benzoyl peroxide Captopril CAPOTEN Amlodipine NORVASC DESQUAM MIOSTAT Amorolfine† LOCERYL Benzphetamine DIDREX Carbachol CARBASTAT Amoxapine ASENDIN Benztropine COGENTIN Carbamazepine TEGRETOL AMOXIL Bepridil VASCOR Carbenicillin GEOCILLIN Amoxicillin POLYMOX CELESTONE Carbidopa LODOSYN TRIMOX Betamethasone UTICORT Carbimazole NEO-MERCAZOLE Amphetamine ADDERAL VALISONE Carboplatin PARAPLATIN Amphotericin B FUNGIZONE BETOPTIC Betaxolol Carisoprodol SOMA OMNIPEN KERLONE CARTROL Ampicillin POLYCILLIN Bethanechol URECHOLINE Carteolol OCUPRESS PRINCIPEN Bleomycin BLENOXANE Carvedilol COREG Amprenavir AGENERASE Bicalutamide CASODEX LIST OF GENERIC VS. TRADE NAMES TM Enhancing Clinical Excellence The following compilation of trade vs. generic drugs was put together for your convenience & reference. It is in no way complete, please refer to Drugs@FDA at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ for complete and most recent list. Generic Trade Generic Trade Generic Trade Caspofungin CANCIDAS Ciclopirox LOPROX NEORAL NEOLOID Cidofovir VISTIDE Cyproheptadine PERIACTIN Castor oil EMULSOIL Cilostazol PIETAL Cyproterone ANDROCUR Cefaclor CECLOR Cimetidine TAGAMET Cytarabine CYTOSAR-U 2-chlorodeox- Cefadroxil DURICEF CILOXAN CLADRIBINE Ciprofloxacin adenosine Cefamandole MANDOL CIPRO Dabigatran PRADAXA ANCEF; KEFZOL Cisplatin PLATINOL Cefazolin Dacarbazine DTIC ZOLICEF Citalopram CELEXA Daclizumab ZENAPAX Cefdinir OMNICEF Cladribine LEUSTATIN Dactinomycin COSMEGEN Cefditoren SPECTRACEF Clarithromycin BIAXIN Dalfopristin See Quinapristin Cefepime MAXIPIME Clemastine TAVIST Dalteparin FRAGMIN Cefixime SUPRAX Clidinium QUARZAN Danazol DANOCRINE Cefoperazone CEFOBID Clindamycin CLEOCIN Dantrolene DANTRIUM Cefotaxime CLAFORAN Clocortolone CLODERM Dapsone Gel ACZONE Cefotetan CEFOTAN Clobetasol TEMOVATE Darbepoetin alpha ARANESP Cefoxitin MEFOXIN Clofazimine LAMPRENE Daunorubicin CERUBIDINE Cefpodoxime VANTIN Clofibrate ATROMID-S Deferoxamine DESFERAL Cefprozil CEFZIL CLOMID Clomiphene Delavirdine RESCRIPTOR Ceftaroline fosamil TELFARO SEROPHENE Demecarium HUMORSOL FORTAZ Clomipramine ANAFRANIL Demeclocycline DECLOMYCIN Ceftazidime TAZICEF Clonazepam KLONOPIN NORPRAMIN TAZIDIME Clonidine CATAPRES Desipramine PERTOFRANE Ceftibuten CEDAX Clopidogrel PLAVIX DDAVP Ceftizoxime CEFIZOX Clorazepate TRANXENE Desmopressin STIMATE Ceftriaxone ROCEPHIN LOTRIMIN Clotrimazole Deslorelin SOMAGARD CEFTIN MYCELEX Cefuroxime TRIDESILON ZINACEF Clotrimazole topical CANESTEN Desonide DESOWEN Celecoxib CELEBREX Cloxacillin TEGOPEN Desoximetasone TOPICORT Cephalexin KEFLEX Clozapine CLOZARIL Detemir LEVEMIR Cephradine VELOSEF FOTOTAR Coal tar DECADRON Cetirizine ZYRTEC ZETAR Dexamethasone HEXADROL Chlorambucil LEUKERAN Colesevelam WELCHOL Dexbrompheniramine DRIXORAL Chloramphenicol CHLOROMYCETIN Colestipol COLESTID Dexchlorpheniramine POLARAMINE Chlordiazepoxide LIBRIUM Colistin COLY-MYCIN PROMIT Chlorhexidine HIBICLENS Corticotropin (ACTH) ACTHAR Dextrans MACRODEX Chlormezanone TRANCOPAL CORTEF Cortisol GENTRAN Chloroquine ARALEN HYDROCORTONE Dextroamphetamine DEXADRINE Chlorothiazide DIURIL Cosyntropin CORTROSYN BENYLIN DM See Trimethoprim Chlorotrianisene TACE Co-trimoxazole Dextromethorphan sulfamethoxazole DELSYM CHLOR-TRIMETON Chlorpheniramine CROLOM; INTAL VALIUM TELDRIN Cromolyn Diazepam NASALCROM DIASTAT Chlorpromazine THORAZINE Cyclandelate CYCLOSPASMOL HYPERSTAT Chlorpropamide DIABINESE Diazoxide Cyclizine MARAZINE PROGLYCEM Chlorthalidone HYGROTON Cyclobenzaprine FLEXERIL CATAFLAM PARAFLEX Diclofenac Chlorzoxazone Cyclopentolate CYCLOGYL VOLTAREN PARAFON FORTE Diclofenac with Cyclophosphamide CYTOXAN ARTHROTEC Cholestyramine QUESTRAN misoprostol Cycloserine SEROMYCIN Choline magnesium TRILISATE DYCILL trisalicylate Cyclosporine SANDIMMUNE Dicloxacillin DYNAPEN LIST OF GENERIC VS. TRADE NAMES TM Enhancing Clinical Excellence The following compilation of trade vs. generic drugs was put together for your convenience & reference. It is in no way complete, please refer to Drugs@FDA at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ for complete and most recent list. Generic Trade Generic Trade Generic Trade PATHOCIL Dutasteride AVODART Etretinate TEGISON Dicyclomine BENTYL Dyclonine DYCLONE Famciclovir FAMVIR Didanosine (ddl) VIDEX DILOR Famotidine PEPCID Dyphylline Diethylcarbamazine HETRAZAN LUFYLLIN Felbamate FELBATOL TENUATE Echothiophate PHOSPHOLINE Felodipine PLENDIL Diethylpropion TEPANIL Econazole SPECTAZOLE ANTARA Diethylstilbestrol STILPHOSTROL Econazole topical ECOSTATIN Cream LIPOFEN Fenofibrate Diethyltoluamide Edetate calcium CALCIUM DISODIUM TRICOR OFF disodium VERSENATE (DEET) TRIGLIDE Diflorasone MAXIFLOR Edrophonium TENSILON Fenoprofen NALFON Diflunisal DOLOBID Efavirenz SUSTIVA Fenoterol nebules BEROTEC Digitoxin† DIGITALINE Eflornithine VANIQA Fentanyl SUBLIMAZE Digoxin LANOXIN Emedastine EMADINE Fentanyl patch DURAGESIC D.H.E. 45 Enalapril VASOTEC Dihydroergotamine Ferrous sulfate FEOSOL MIGRANAL Enoxacin PENETREX Fexofenadine ALLEGRA CARDIZEM Enoxaparin LOVENOX Diltiazem Fidaxomicin DIFICID DILACOR Entacapone COMTAN Finasteride PROSCAR Dimenhydrinate DRAMAMINE Epinephrine ADRENALIN Flecainide TAMBOCOR Dimercaprol BAL Epirubicin ELLENCE Fluconazole DIFLUCAN Dimethyl sulfoxide RIMSO-50 Eplerenone INSPRA Flucytosine ANCOBON BENADRYL Epoprostenol FLOLAN Fludarabine FLUDARA Diphenhydramine NYTOL Eprosartan TEVETEN Fludrocortisone FLORINEF SOMINEX Eptifibatide INTEGRILIN Flunisolide NASALIDE LOMOTIL Ergocalciferol DRISDOL Diphenoxylate with Fluocinolone SYNALAR atropine MOTOFEN ERGOMAR Fluocinonide LIDEX PROPINE Ergotamine ERGOSTAT Dipivefrin Fluorouracil ADRUCIL AK Pro CAFERGOT Fluorouracil (topical) EFUDEX Dipyridamole PERSANTINE Ertapenem INVANZ Fluoxetine PROZAC Dirithromycin DYNABAC E-MYCIN Fluoxymesterone HALOTESTIN Disopyramide NORPACE Erythromycin ERYTHROCIN PERMITIL Disulfiram ANTABUSE ILOSONE Fluphenazine PROLIXIN Divalproex DEPAKOTE EPOGEN Erythropoietin Flurandrenolide CORDRAN Dobutamine DOBUTREX PROCRIT Flurazepam DALMANE Docetaxel TAXOTERE Escitalopram CIPRALEX ANSAID Docosanol ABREVA CLIMARA Flurbiprofen OCUFEN Docusate COLACE ESTALIS FROBEN Donepezil ARICEPT ESTRACOMB Estradiol patches Flutamide EULEXIN Dopamine INTROPIN ESTRADERM CUTIVATE Dorzolamide TRUSOPT ESTRADOT Fluticasone FLONASE Doxazosin CARDURA ESTROGEL FLOVENT SINEQUAN Estrogens PREMARIN Doxepin Fluvastatin LESCOL ZONALON Etanercept ENBREL Fluvoxamine LUVOX Doxorubicin ADRIAMYCIN Ethacrynic acid EDECRIN Fomivirsen VITRAVENE Doxycycline VIBRAMYCIN Ethambutol MYAMBUTOL Fondaparinux ARIXTRA Doxylamine NYQUIL Ethosuximide ZARONTIN Formoterol FORADIL Dronabinol MARINOL ENDRATE Ethylenediaminetetraa Foscarnet FOSCAVIR Drotrecogin alfa cetic acid (EDTA) VERSENATE XIGRIS Fosfomycin MONUROL (activated) Etidronate DIDRONEL Fosinopril MONOPRIL Duloxetine CYMBALTA Etodolac LODINE Fosphenytoin CEREBYX LIST OF GENERIC VS. TRADE NAMES TM Enhancing Clinical Excellence The following compilation of trade vs. generic drugs was put together for your convenience & reference. It is in no way complete, please refer to Drugs@FDA at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al
    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Brimonidine Tartrate; Brinzolamide
    Contains Nonbinding Recommendations Draft Guidance on Brimonidine Tartrate ; Brinzolamide This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Brimonidine tartrate; Brinzolamide Dosage Form; Route: Suspension/drops; ophthalmic Strength: 0.2%; 1% Recommended Studies: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm, in vivo Strength: 0.2%; 1% Subjects: Males and females with chronic open angle glaucoma or ocular hypertension in both eyes. Additional comments: Specific recommendations are provided below. ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open angle glaucoma and ocular hypertension comparing the test product to the reference listed drug (RLD), each applied as one drop in both eyes three times daily at approximately 8:00 a.m., 4:00 p.m., and 10:00 p.m. for 42 days (6 weeks). 2. Inclusion criteria (the sponsor may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes b.
    [Show full text]
  • This Table Summarizes Changes to the HF Qxq As of 10/11/2019 Question
    Updated HFS Instructions (QxQs) This table summarizes changes to the HF QxQ as of 10/11/2019 Question in HF QxQ Description of Changes in HF QXQ General Instructions, pg. 3 Clarification added to rules for history Q29.d.10., pg. 40 Clarification made on how to record pulmonary hypertention Q29.d.14., pg. 41 Clarification made on how to record diastolic dysfunction Q42., pg. 42 Clarification made on how to record troponin I Section VII: Medication, pg. 54 Clarificaiton made on how to record medications Appendix A, pg. 61 Updated list of medications Edoxaban (ACOAG, Generic) Lixiana (ACOAG, Trade) Prexxartan (ARB, Trade) INSTRUCTIONS FOR COMPLETING HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM HFS Version C, 10/1/2015 HFA Version D, 10/1/2015 HF QxQ, 10/11/2019 Table of Contents Page General Instructions……………………………………………………………….. 2 Specific Items………………………………………………………………………. 3 Section l: Screening for Decompensation………………………………….. 5 Section ll: History of Heart Failure…………………………………………... 10 Section lll: Medical History ………………………………………………….. 13 Section lV: Physical Exam - Vital Signs…………………………………….. 24 Section V: Physical Exam - Findings……………………………………….. 26 Section Vl: Diagnostic Tests…………………………………………………. 31 Section Vll: Biochemical Analyses………………………………………….. 48 Section Vlll: Interventions…………………………………………………….. 51 Section lX: Medications………………………………………………………. 54 Section X: Complications Following Events………………………………… 59 Section Xl: Administrative……………………………………………………. 60 Appendix A: ARIC Heart Failure/Cardiac Drugs: ………………………………. 61 Alphabetical Sort Appendix B: Potential Scenarios of the Onset of Heart………………………. 73 Failure Event or Decompensation HF QxQ 10/11/2019 Page 1 of 73 General Instructions The HFAA form was initially used for all discharges selected for HF surveillance. It was replaced by the HFAB and HFSA forms and then updated June 2012 with HFAC and HFSB.
    [Show full text]
  • MIRADON FPO Brand of Anisindione Tablets
    R 1 2 3 4 5 3 4 F-16099775 1898 ® MIRADON FPO brand of anisindione Tablets DESCRIPTION MIRADON Tablets contain a syn- thetic anticoagulant, anisindione, an indanedione derivative. Each tablet contains 50 mg anisin- dione. They also contain: corn starch, FD&C Red No. 3, gelatin, lactose, and hydrogenated cotton- seed oil. ACTIONS Like phenindione, to which it is re- lated chemically, anisindione exercises its thera- peutic action by reducing the prothrombin activity of the blood. INDICATIONS Anisindione is indicated for the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrilla- tion with embolization, the prophylaxis and treat- ment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion. CONTRAINDICATIONS All contraindications to oral anticoagulant therapy are relative rather than absolute. Contraindications should be evaluated for each patient, giving consideration to the need for and the benefits to be achieved by anticoagu- lant therapy, the potential dangers of hemor- rhage, the expected duration of therapy, and the quality of patient monitoring and compliance. Hemorrhagic Tendencies or Blood Dyscrasias: In general, oral anticoagulants are contraindi- cated in patients who are bleeding or who have hemorrhagic blood dyscrasias or hemorrhagic tendencies (eg, hemophilia, polycythemia vera, purpura, leukemia) or a history of bleeding dia- thesis. They are contraindicated in patients with recent cerebral hemorrhage, active ulceration of the gastrointestinal tract, including ulcerative colitis, or open ulcerative, traumatic, or surgical wounds. Oral anticoagulants may be contraindi- cated in patients with recent or contemplated brain, eye, or spinal cord surgery or prostatec- tomy, and in those undergoing regional or lumbar block anesthesia or continuous tube drainage of the small intestine.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Levobetaxolol Hydrochloride
    1882 Miotics Mydriatics and Antiglaucoma Drugs if necessary 5 to 10 minutes later. In the treatment of uveitis Herpes simplex dendritic keratitis developed in 2 patients during Levobetaxolol Hydrochloride (USAN, rINNM) ⊗ (p.1515), the eye drops should be instilled two or three times dai- latanoprost therapy.3 The author suggested that the biochemical ly, or up to every 3 to 4 hours if required. changes in the cornea caused by latanoprost may predispose to AL-1577A (levobetaxolol or levobetaxolol hydrochloride); Hid- herpes keratitis. rocloruro de levobetaxolol; Lévobétaxolol, Chlorhydrate de; The BNFC recommends that eye drops containing 0.5% homat- Levobetaxololi Hydrochloridum. (−)-(S)-1-{p-[2-(Cyclopropyl- ropine hydrobromide are used once daily or on alternate days for 1. Wardrop DRA, Wishart PK. Latanoprost and cystoid macular methoxy)ethyl]phenoxy}-3-isopropylaminopropan-2-ol hydro- uveitis in children aged 3 months to 2 years; older children may oedema in a pseudophake. Br J Ophthalmol 1998; 82: 843–4. be given 1 or 2% eye drops twice daily. 2. Stewart O, et al. Bilateral optic disc oedema associated with chloride. latanoprost. Br J Ophthalmol 1999; 83: 1092–3. Левобетаксолола Гидрохлорид Homatropine has also been used as the quaternary ammonium 3. Ekatomatis P. Herpes simplex dendritic keratitis after treatment methobromide derivative in the treatment of gastrointestinal with latanoprost for primary open angle glaucoma. Br J Ophthal- C18H29NO3,HCl = 343.9. spasm and as an adjunct in peptic ulcer disease; homatropine mol 2001; 85: 1008–9. CAS — 93221-48-8 (levobetaxolol); 116209-55-3 (levo- betaxolol hydrochloride). methobromide has also been included in preparations used for Systemic effects.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • Ophthalmic Agents, Intraocular Pressure (IOP)-Modifying
    Therapeutic Class Overview Ophthalmic Agents, Intraocular Pressure (IOP)-Modifying INTRODUCTION Glaucoma is an optic neuropathy that causes gradual degeneration of the cells making up the optic nerve. Glaucoma is among the leading causes of blindness worldwide, and in 2020, an estimated 3.2 million people worldwide are anticipated to be blind due to glaucoma (Flaxman et al 2017). Open-angle glaucoma is the most common form; other forms include angle-closure, congenital, and secondary glaucoma (Jacobs 2018[a]). Patients with open-angle glaucoma initially experience peripheral visual field loss, followed by central field loss, which may progress to irreversible blindness if untreated (Jacobs 2018[a]). The exact etiology of open-angle glaucoma is unknown (Jacobs 2018[a]). Major risk factors for developing open-angle glaucoma include advanced age, African or Hispanic/Latino descent, elevated intraocular pressure (IOP), family history of glaucoma, low ocular perfusion pressure, type 2 diabetes mellitus, and myopia (Ellis et al 2000, Girkin et al 2004, Lesk et al 2007, Prum et al 2016). Elevated IOP is the only major risk factor for glaucoma that is treatable. Available evidence suggests that lowering IOP inhibits or reduces the progression of optic nerve damage (Jacobs 2018[a]). Treatment may be initiated in patients with a raised IOP despite having no visual field loss or optic nerve damage (Jacobs 2018[a]). An IOP > 22 to 25 mmHg is generally considered to be elevated and would be treated by most clinicians; however, this number varies according to screening methods, risk factors, and disease progression (Jacobs 2018[b]). The target IOP should be individualized based on response to therapy and disease progression in order to maintain IOP within a range that is unlikely to adversely affect patients’ health-related quality of life (Jacobs 2018[b]).
    [Show full text]
  • Jan 19, 2009 Listing of Generic, Non
    http://www.medword.com/uspa.html Jan 19, 2009 Listing of generic, non-prescription, prescription, and OTC (over-the-counter) p harmaceuticals A-200 Gel Concentrate A-200 Shampoo Concentrate A-25 A-Cillin A-Fil A-Hydrocort A-methaPred A-Phedrin A-Spas S/L A Plus A.C. & C. A.P.L. A.R.M. Allergy Relief A.R.M. Maximum Strength Caplets A/B Otic A/Fish Oil A/T/S abacavir abarelix-depot-F abarelix-depot-M Abbokinase Abbokinase Open-Cath Abelcet Abenol Abitrate Absorbine Athletes Foot Absorbine Jock Itch Absorbine Jr. Antifungal AC acarbose Accolate Accupep HPF Accupril Accuretic Accutane Accutane Roche acebutolol Acel-Imune Acellular DTP Aceon Acet-2 Acet-3 Acet Codeine 30 Acet Codeine 60 Aceta Aceta Elixir Aceta Tablets acetaminophen acetaminophen-butalbital acetaminophen-caffeine acetaminophen-chlorpheniramine acetaminophen-codeine acetaminophen-dextromethorphan acetaminophen-diphenhydramine acetaminophen-hydrocodone acetaminophen-oxycodone acetaminophen-phenyltoloxamine acetaminophen-propoxyphene acetaminophen-propoxyphene hydrochloride acetaminophen-propoxyphene napsylate acetaminophen-pseudoephedrine acetazolam acetazolamide Acetest acetic acid Acetocot acetohexamide acetophenazine Acetoxyl 10 Gel Acetoxyl 2.5 Gel Acetoxyl 20 Gel Acetoxyl 5 Gel acetylsalicylic acid Achromycin Achromycin V aciclovir Acid Control Acid Phos Fluor Rinse Acilac Aciphex acitretin Aclophen Aclovate Acne-10 Lotion Acne-5 Lotion Acne-Aid Aqua Gel Acne-Aid Gel Acne-Aid Vanishing Cream Acne Aid 10 Cream Acne Lotion 10 Acne Prone Skin Sunscreen Acne Wash Acno Acnomel
    [Show full text]
  • Sheet1 Page 1 a Abamectin Acetazolamide Sodium Adenosine-5-Monophosphate Aklomide Albendazole Alfaxalone Aloe Vera Alphadolone A
    Sheet1 A Abamectin Acetazolamide sodium Adenosine-5-monophosphate Aklomide Albendazole Alfaxalone Aloe vera Alphadolone Acetate Alpha-galactosidase Altrenogest Amikacin and its salts Aminopentamide Aminopyridine Amitraz Amoxicillin Amphomycin Amphotericin B Ampicillin Amprolium Anethole Apramycin Asiaticoside Atipamezole Avoparcin Azaperone B Bambermycin Bemegride Benazepril Benzathine cloxacillin Benzoyl Peroxide Benzydamine Bephenium Bephenium Hydroxynaphthoate Betamethasone Boldenone undecylenate Boswellin Bromelain Bromhexine 2-Bromo-2-nitropan-1, 3 diol Bunamidine Buquinolate Butamisole Butonate Butorphanol Page 1 Sheet1 C Calcium glucoheptonate (calcium glucoheptogluconate) Calcium levulinate Cambendazole Caprylic/Capric Acid Monoesters Carbadox Carbomycin Carfentanil Carnidazole Carnitine Carprofen Cefadroxil Ceftiofur sodium Centella asiatica Cephaloridine Cephapirin Chlorine dioxide Chlormadinone acetate Chlorophene Chlorothiazide Chlorpromazine HCl Choline Salicylate Chondroitin sulfate Clazuril Clenbuterol Clindamycin Clomipramine Clopidol Cloprostenol Clotrimazole Cloxacillin Colistin sulfate Copper calcium edetate Copper glycinate Coumaphos Cromolyn sodium Crystalline Hydroxycobalamin Cyclizine Cyclosporin A Cyprenorphine HCl Cythioate D Decoquinate Demeclocycline (Demethylchlortetracycline) Page 2 Sheet1 Deslorelin Desoxycorticosterone Pivalate Detomidine Diaveridine Dichlorvos Diclazuril Dicloxacillin Didecyl dimethyl ammonium chloride Diethanolamine Diethylcarbamazine Dihydrochlorothiazide Diidohydroxyquin Dimethylglycine
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Levobetaxolol (hydrochloride) Item No. 33435 CAS Registry No.: 116209-55-3 Formal Name: (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl] phenoxy]-3-[(1-methylethyl)amino]-2- propanol, monohydrochloride O Synonym: (S)-Betaxolol MF: C18H29NO3 • HCl • HCl FW: 343.9 N O Purity: ≥98% H OH Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Levobetaxolol (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the levobetaxolol (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Levobetaxolol (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of levobetaxolol (hydrochloride) in ethanol is approximately 1 mg/ml and approximately 10 mg/ml in DMSO and DMF. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of levobetaxolol (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of levobetaxolol (hydrochloride) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Levobetaxolol is an isomer of betaxolol (Item No. 18625) and antagonist of the β1-adrenergic receptor 1 (β1-AR; Ki = 0.76 nM for the human receptor). It is selective for β1-ARs over β2-ARs (Ki = 32.6 nM), as well as a panel of 89 additional receptors (IC50s = >1 µM).
    [Show full text]